CA 19-9 blood test: what it measures, normal levels, what a high level means, and why it is not a screening test

CA 19-9 is a carbohydrate antigen — a sugar structure attached to proteins and fats on the surface of cells lining the pancreatic and bile ducts, the stomach, the colon and the salivary glands. Cells shed small amounts into the blood normally. When those tissues are inflamed, blocked or replaced by tumor, far more enters the circulation, and the blood test measures that concentration in units per milliliter (U/mL).

It is classed as a tumor marker because pancreatic adenocarcinoma is the cancer most likely to push it far above normal: roughly three-quarters of people with pancreatic cancer have an elevated CA 19-9 at diagnosis, and the level tends to track the amount of disease. Bile-duct (cholangiocarcinoma), gallbladder, stomach and colorectal cancers can also raise it, as can some ovarian and lung tumors.

The crucial limitation is that the antigen is not specific to cancer. Anything that blocks or inflames the bile ducts — a gallstone in the common duct, cholangitis, cirrhosis, hepatitis — can raise CA 19-9 substantially, sometimes into the hundreds. That is why the number is read alongside imaging and liver tests rather than on its own.

Most laboratories report a reference range of 0 to 37 U/mL; the exact cutoff varies slightly by assay, and the range printed on your report applies. Values are only comparable between tests run on the same assay at the same lab, which matters when the number is being followed over time.

Because CA 19-9 is used to follow a known disease, laboratories emphasize the trend more than any single value. A result that doubles between two draws carries more information than a single result that sits modestly above the cutoff.

Pancreatic cancer is uncommon in the general population, and CA 19-9 rises in many people who do not have it. When a test with those two properties is applied to healthy adults, most positive results are false positives — one large screening study found that fewer than one in a hundred people with an elevated CA 19-9 turned out to have pancreatic cancer. Guideline bodies including the American Society of Clinical Oncology and the National Cancer Institute therefore do not recommend CA 19-9 for screening people without symptoms.

There is also a false-negative problem. CA 19-9 is built on the Lewis blood-group antigen, and roughly 5–10% of people are genetically Lewis-negative: their cells cannot produce the antigen, so their CA 19-9 stays low or undetectable even with extensive cancer. A normal result cannot rule cancer out in that group, and there is no routine way to know who they are without a separate test.

Where the marker does earn its place is in someone who already has a suspicious finding — a pancreatic mass on CT, painless jaundice, new-onset diabetes with weight loss — or a confirmed diagnosis. In those settings the baseline value, its response to surgery or chemotherapy and its trajectory afterwards are genuinely useful.

Oncologists order CA 19-9 at diagnosis of pancreatic or bile-duct cancer to establish a baseline, before and after surgery to gauge whether the tumor was fully removed, during chemotherapy to see whether the treatment is working, and at intervals afterwards to watch for recurrence — a rising level often precedes visible recurrence on scans by weeks to months.

Gastroenterologists sometimes add it when working up a pancreatic cyst, an unexplained pancreatic mass or a bile-duct stricture, to weigh the likelihood of malignancy alongside imaging and biopsy. It is also drawn in people with a strong family history or a known genetic syndrome who are enrolled in a high-risk surveillance program, though imaging is the mainstay there.

Some people order it themselves out of concern about pancreatic cancer. It is worth understanding before doing so that a normal result does not exclude cancer (especially in Lewis-negative individuals), an abnormal result is most often caused by something else, and the test has no proven benefit as a stand-alone screen.

The causes fall into two groups, and the benign group is larger than most people expect. Causes are listed roughly from most to least common in people who are tested:

A raised CA 19-9 in someone without a known cancer is a prompt for evaluation, not a diagnosis. The usual first steps are a careful history (pain, jaundice, weight loss, new diabetes, alcohol use), a hepatic function panel and lipase to look for bile-duct obstruction or pancreatitis, and imaging — typically a contrast CT of the abdomen or an MRI/MRCP of the pancreas and bile ducts. If those are normal, many clinicians simply repeat the marker in a few weeks, because transient elevations from a passing gallstone or infection resolve on their own.

In someone with a known cancer, the meaning depends on timing. A fall toward normal after surgery suggests the tumor was removed; a level that stays high or rises suggests residual disease. During chemotherapy, a fall of roughly 20–50% from baseline is commonly used as a sign of response, and a steady rise usually triggers restaging scans. The exact thresholds are set by the treating oncologist, because they depend on the starting level and the assay.

Two practical cautions: never interpret a CA 19-9 drawn while jaundiced, and always trend results from the same laboratory. Switching labs mid-treatment can create an apparent rise or fall that is purely a difference in assay calibration.

CA 19-9 is a standard blood draw with no fasting or preparation, run at Quest and Labcorp with results in a few business days. You can have it ordered by your doctor or oncologist, or order it yourself through TestWell and walk into a patient service center; a licensed physician reviews the order and the report posts to your portal with the lab's reference range. Because the marker is most useful as a trend, keep the report and use the same lab for any repeat.

If you are ordering it because of symptoms — persistent upper abdominal or back pain, unexplained weight loss, yellowing of the skin or eyes, pale stools or dark urine — see a clinician rather than waiting on a marker. Those symptoms warrant imaging regardless of what CA 19-9 shows.